NHS Hospital Drug Costs Are Set to Surpass Spending in Primary Care

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.k1766

2018-01-01

BMJ

Abstract:An explosive growth in hospital drug spending is set to overturn the longstanding pattern of the NHS medicine budget, Nigel Hawkes reports

What problem does this paper attempt to address?

Cost Of Hospital Prescribing Rose 15% In A Year Owing To New Rheumatoid Arthritis And Cancer Drugs

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.g6867

2014-01-01

Abstract:The total cost to the NHS in England of prescribed drugs rose by more than £1bn to £14.4bn (€18.2bn; $22.7bn) in 2013-14, new data from the Health and Social Care Information Centre show.1 By far the sharpest rise was in hospital prescribing, where the total spend rose by 15.1% to almost £5.8bn. The total spend in primary care was greater, at almost £8.5bn, but the increase over 2012-13 was smaller, at 3.2%. The faster rise in hospital spending was attributed to the introduction of innovative drugs, which are more likely to be dispensed in hospitals and which are in general more expensive. Seven prescribed drugs cost more than …
Nice Sets Cap On Drugs Costing More Than 20m Pound

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.j1372

2017-01-01

Abstract:The Association of the British Pharmaceutical Industry has accused the government of breaking its promise to speed up the introduction of cost effective drugs into the NHS.The association said that proposals by the National Institute for Health and Care Excellence (NICE) and NHS England to refuse to pay for any new drug that will cost more than £20m (€23m; $24m) a year was a breach of a pledge made in the Conservative Party’s election manifesto in 2015.The decision means that new drugs would not only have to meet NICE’s threshold of cost effectiveness—set at about £20 000 to £30 000 …
English Nhs Could Be 54bn Pound In Red By 2021 If Budget Or Output Doesn'T Increase

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.e8208

2012-01-01

British Medical Journal

Abstract:The current squeeze on NHS spending in England is no short term measure but is likely to be sustained for many years, the Nuffield Trust has warned in a new report. Without unprecedented gains in productivity or an economic turnaround leading to greater spending, the total costs incurred in running the health service in England are likely to exceed the cash available by a cumulative total of as much as £54bn (€66bn; $86bn) by 2021-2, says the report.1 This worst case scenario assumes that the current efforts to achieve efficiency gains of 4% a year to 2014-5 (the “Nicholson challenge”) fail, that funding remains flat in real terms, and that demand continues to grow at the historical rate of 4% a year throughout the period. If any of these assumptions is changed for the better, the gap narrows. It would be eliminated totally if …
Any Foreseeable Growth in Nhs Will "feel Like A Cut" Because of Demographics and Cost Inflation, Report Says

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.e4587

2012-01-01

British Medical Journal

Abstract:The NHS in England faces a decade of austerity, and a squeeze on spending is likely to last at least until 2021-2, concludes a new analysis commissioned by the Nuffield Trust and carried out by the Institute for Fiscal Studies.1 In spite of the relative protection given to health spending by the government, demographic changes and cost inflation mean that under almost any imaginable scenario the NHS budget will rise more slowly than the likely demand. The immediate challenge of making £15bn (€20bn; $24bn) to £20bn of savings in four years during this parliament—the tightest four year period of funding for the NHS in the past half century—will continue into the next four years. “If NHS productivity does not increase sufficiently fast to bridge the gap between funding and demand pressures, then access to and quality of care is likely to deteriorate,” the report says. “Serious thought must …
Choosing Drugs on Price Alone Will Stifle Innovation, Says Report

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.i6065

2016-01-01

BMJ

Abstract:The NHS in England should not focus exclusively on price when buying medicines, says a new report published by the London School of Economics (LSE).1Doing so risks endangering constructive partnerships between clinicians, NHS managers, and drug companies and conflicts with the government’s aim of balancing affordability with encouraging innovation, the report warned.While the Pharmaceutical Price Regulation Scheme and HM Treasury both seek to strike this balance, the report warned that growing pressure on NHS budgets will encourage cost saving to the detriment of cooperation and innovation.Tender Loving Care? was written by Andrew Bonser, a consultant who has worked for Pfizer and Boots; Panos Kanavos, deputy director of LSE Health; and David Taylor, emeritus professor of pharmaceutical and public health policy at University College London. It was commissioned and funded …
NHS overspend reaches £2.3bn

Susan Mayor

DOI: https://doi.org/10.1136/bmj.i1072

2016-01-01

Abstract:The NHS overspent by £2.26bn (€2.9bn; $3.2bn) in the first three quarters of this financial year (April to December 2015), a report from Monitor and the NHS Trust Development Authority showed.1 The overspend is forecast to reach £2.37bn by the end of March.The deficit is £622m more than planned for by the health regulators. The planned £1.6bn was reached at the end of the second quarter. Providers were told that the deficit must be kept below £1.8bn.“This level of deficit is neither sustainable nor affordable …
The increasing costs of medicines and their implications for patients, physicians and the health system

Narcyz Ghinea

DOI: https://doi.org/10.1111/imj.16370

2024-04-06

Internal Medicine Journal

Abstract:Most new medicines entering the market are high‐cost speciality drugs. These drugs can cost tens to hundreds of thousands of dollars per course of treatment and in some cases millions of dollars per dose. Approximately half of all spending on medicines is projected to target only 2–3% of patients, raising important questions about resource allocation. While there is no doubt that breakthrough innovations have transformed clinical care in some disciplines, it is also true that cost is becoming one of the primary barriers to treatment access and that many new medicines do not provide value commensurate with their prices. This article examines pricing trends, the reasons for high prices and their implications for access and clinical practice.

medicine, general & internal
National trends in prescription drug expenditures and projections for 2024

Eric M Tichy,James M Hoffman,Mina Tadrous,Matthew H Rim,Sandra Cuellar,John S Clark,Mary Kate Newell,Glen T Schumock

DOI: https://doi.org/10.1093/ajhp/zxae105

2024-04-24

American Journal of Health-System Pharmacy

Abstract:Abstract Disclaimer In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2024 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2024 were reviewed—including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, endocrine drugs, generics, and specialty drugs. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2024 were based on a combination of quantitative analyses and expert opinion. Results In 2023, overall pharmaceutical expenditures in the US grew 13.6% compared to 2022, for a total of $722.5 billion. Utilization (a 6.5% increase), new drugs (a 4.2% increase) and price (a 2.9% increase) drove this increase. Semaglutide was the top drug in 2023, followed by adalimumab and apixaban. Drug expenditures were $37.1 billion (a 1.1% decrease) and $135.7 billion (a 15.0% increase) in nonfederal hospitals and clinics, respectively. In clinics, increased utilization drove growth, with a small impact from price and new products. In nonfederal hospitals, a drop in utilization led the decrease in expenditures, with price and new drugs modestly contributing to growth in spending. Several new drugs that will influence spending are expected to be approved in 2024. Specialty, endocrine, and cancer drugs will continue to drive expenditures. Conclusion For 2024, we expect overall prescription drug spending to rise by 10.0% to 12.0%, whereas in clinics and hospitals we anticipate an 11.0% to 13.0% increase and a 0% to 2.0% increase, respectively, compared to 2023. These national estimates of future pharmaceutical expenditure growth may not be representative of any health system because of the myriad of local factors that influence actual spending.

pharmacology & pharmacy
The Travesty of Expensive Insulin

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.i2933

2016-01-01

Abstract:A bad precedent for future drug pricing
Between a Fifth and a Third of Hospitals Record Inaccurate Cost Data

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.g4021

2014-01-01

BMJ

Abstract:A third of NHS trusts in England submit annual cost data that are “materially incorrect” and half have poor costing in at least one important area of activity, a snapshot survey of 50 trusts by the health analytics company CHKS Capita has shown.1 But the results may exaggerate the failings, since 60% of the trusts selected for auditing were chosen because they were suspected of being poor at costing. In the remaining 40%, which were chosen at random, only a fifth had inaccurate data. Every year each hospital trust submits reference cost data to the Department of Health. Each reference cost is the cost incurred by the organisation to produce one unit of activity, where units of activity are categorised by type (day case, outpatient, emergency admission, and so on), specialty, and healthcare resource group (HRG), which defines the condition treated. The volume …
When the price is right: drug costing and NICE approval.

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.i6519

2016-01-01

Abstract:Price discounts are leading to a flurry of NICE approvals. Nigel Hawkes investigatesAfter years of standoffs and angry words, drug companies are cutting prices of cancer treatments in a bid to gain approval for use in the NHS in England.This change of policy, unpredicted when the old Cancer Drugs Fund was wound up in July,1 has analysts puzzled. Has the industry finally recognised that its products are not worth as much as it once claimed? Or is there a subtle plan to clear the decks of unapproved drugs to make room in the revamped Cancer Drugs Fund for yet more expensive ones coming down the pipeline?Whatever the reason, the result has been to allow the National Institute for Health and Care Excellence to approve, at the draft or final guidance stage, seven of the first nine drugs it has reviewed from the old Cancer Drugs Fund list.2 In November NICE approved three drugs for breast cancer in as many weeks and reversed …
Hospitals’ Reported £1bn Deficit Masks True Scale of Financial Woes, Say Analysts

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.k2432

2018-01-01

BMJ

Abstract:Hospitals spent almost £1bn more in 2017-18 than they were paid, show data published by NHS Improvement.1 The provider sector as a whole ended the year with a deficit of £960m (€1.1bn; $1.3bn), which is almost exactly balanced by a projected underspend of £955m by healthcare commissioners reported last week by NHS England. The NHS as a whole is therefore “broadly in balance,” said NHS Improvement, which oversees providers of NHS services. However, analysts questioned the conclusion, claiming that it was achieved only by one-off savings and a non-recurrent £1.8bn transfer from the sustainability and transformation fund set up to help transform NHS services.2 If these were discounted, said Sally Gainsbury, senior policy analyst at the think tank the Nuffield Trust, the true provider deficit …
UK Spending on Health Doubled in Past 20 Years

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.h804

2015-01-01

BMJ

Abstract:Spending on health has been the biggest gainer in the United Kingdom in the past 20 years, more than doubling in real terms and outstripping all other major public spending, the Office for National Statistics has reported in an article on its new Visual ONS website.1 Defence spending was among the biggest losers, falling in real terms and as a proportion of all public spending, from 8.7% in 1993-94 to …
England's NHS Faces a Funding Crisis, Report Says.

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.g4515

2014-01-01

BMJ

Abstract:The NHS in England faces a funding crisis this year or the next, as it runs out of easy ways to save money and service transformation remains a distant prospect, the think tank the Nuffield Trust has concluded in a new report.1 Charged with making efficiency savings of 4% a year to balance the books, commissioners and NHS trusts are missing the target by a growing margin, making smaller and smaller savings each year. In 2013-14 clinical commissioning groups made savings of less than 2% of their total spending, while NHS foundation trusts achieved 3%. Although numbers of permanent staff have been cut, spending on agency staff to fill the gaps has risen swiftly enough to swallow any savings. In 2013-14 foundation trusts’ spending on agency staff rose 27%, …
NHS Hospitals Should Imitate Sainsbury's Local and Tesco Metro, Hospital Chief Says.

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.g2416

2014-01-01

BMJ

Abstract:The NHS is “close to being overwhelmed,” the UK shadow health secretary has said. Speaking at a meeting organised by the Reform think tank for the Shelford Group of leading academic hospitals, Andy Burnham said that problems in accident and emergency (A&E) departments were a barometer of wider pressures on health and social care as a whole. “If there is a blockage anywhere, it will be seen in A&E,” he said. He noted that cuts to general practice and community care, as well as to local authorities and social care, had placed hospitals under increasing pressure. “Can they carry on and never drop the ball?” Burnham asked, claiming that A&E targets had been missed for 35 weeks running and that more than a million patients had waited longer in A&E than the target maximum of four hours. “I think if you look at A&E it is telling you the system is close to …
New Models of Healthcare Will Replace Nearly Three Quarters of NHS by 2024, Report Says.

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.g4088

2014-01-01

Abstract:The NHS is in “a crisis of inaction” where the need for change is recognised but is judged too difficult to achieve, a new report for the think tank Reform has claimed.1 It said that false loyalty to existing models of healthcare delivery, high fixed costs of labour and real estate, and resistance to new entrants all worked against the changes that were needed and that had already revolutionised other industries. The report—written by the former Labour health adviser Paul Corrigan and Mike Parish, chief executive of the …
NICE is Too Generous in Approving Drugs, Analysis Says.

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.h955

2015-01-01

BMJ

Abstract:The method used by the National Institute for Health and Care Excellence to assess the value of new drugs in England has done more harm than good, concludes an analysis by the Centre for Health Economics at the University of York.1 And the Cancer Drugs Fund has done even greater harm, it found, saying that the money spent by the fund on expensive cancer drugs would have done five times as much good if spent elsewhere in the NHS. Karl Claxton, lead author of the analysis, told a briefing at the Science Media Centre in London that NHS outcomes would be better if it refused to fund any drug that cost more than £13 000 (€17 500; $20 000) per quality adjusted life year …
Causes of the unduly rapid growth of drug expenses in China and countermeasures

WANG Kerang,LIN Yan,DONG Hengjin

DOI: https://doi.org/10.3760/j.issn:1000-6672.2000.05.019

2000-01-01

Abstract:The unduly rapid growth of drug expenses in China at present exceeds the countrys economic development and patients endurance, turning into one of the central social issues. The paper gives a detailed analysis of the causes of the problem, which can be attributed both to the field of production and the process of consumption. It also puts forward appropriate countermeasures from the perspective of the structure of the drug industry, hospital management, drug prices, doctors supervision and the medical insurance system.
Nhs Must Find Ways To Speed Access To New Drugs And Technologies

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.i5760

2016-01-01

Abstract:New drugs, diagnostic tools, and healthcare technologies could be adopted more quickly if the NHS took a fresh approach, according to the final report of the Accelerated Access Review.1Streamlining the drug approval process could cut four years off the time needed to bring new medicines to the clinic, the review said. This would be made up by saving 12-18 months in the drug approval process; by cutting delays in approval by the National Institute for Health and Care Excellence (NICE), which typically takes up to two years; and in NHS commissioning and adoption, which usually takes another two years.“We need to act now to make the most of a tidal wave of new drugs and technologies that are being developed,” …
Speeding Up Access to New Drugs Threatens Evidence Based Medicine, Says Health Economist

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.i263

2016-01-01

BMJ

Abstract:Accelerating access to new drugs in the NHS will do more harm than good, asserts Karl Claxton, a health economist at the University of York. Expensive new drugs absorb money that, on his calculations, could achieve greater benefits to patients if spent elsewhere in the NHS. Claxton was speaking at a Westminster Health Forum seminar in London and in the 10 minutes allocated to him issued a powerful challenge to the more conventional views being offered by other speakers. The government’s Accelerated Access Review, which seeks to speed new drugs from the laboratory into the clinic (https://www.gov.uk/government/organisations/accelerated-access-review), would “increase the rate of harm” already done by the Cancer Drugs Fund and the National Institute for Health and Care Excellence (NICE), he said. Changes to the Cancer Drugs Fund would …

NHS Hospital Drug Costs Are Set to Surpass Spending in Primary Care

Cost Of Hospital Prescribing Rose 15% In A Year Owing To New Rheumatoid Arthritis And Cancer Drugs

Nice Sets Cap On Drugs Costing More Than 20m Pound

English Nhs Could Be 54bn Pound In Red By 2021 If Budget Or Output Doesn'T Increase

Any Foreseeable Growth in Nhs Will "feel Like A Cut" Because of Demographics and Cost Inflation, Report Says

Choosing Drugs on Price Alone Will Stifle Innovation, Says Report

NHS overspend reaches £2.3bn

The increasing costs of medicines and their implications for patients, physicians and the health system

National trends in prescription drug expenditures and projections for 2024

The Travesty of Expensive Insulin

Between a Fifth and a Third of Hospitals Record Inaccurate Cost Data

When the price is right: drug costing and NICE approval.

Hospitals’ Reported £1bn Deficit Masks True Scale of Financial Woes, Say Analysts

UK Spending on Health Doubled in Past 20 Years

England's NHS Faces a Funding Crisis, Report Says.

NHS Hospitals Should Imitate Sainsbury's Local and Tesco Metro, Hospital Chief Says.

New Models of Healthcare Will Replace Nearly Three Quarters of NHS by 2024, Report Says.

NICE is Too Generous in Approving Drugs, Analysis Says.

Causes of the unduly rapid growth of drug expenses in China and countermeasures

Nhs Must Find Ways To Speed Access To New Drugs And Technologies

Speeding Up Access to New Drugs Threatens Evidence Based Medicine, Says Health Economist